- In every new line of therapy, approximately 50% of patients die, or are lost to follow-up2
- As the disease progresses and becomes resistant to treatment, there are fewer treatment options resulting in poor outcomes for triple class refractory patients, who have less than 12 months overall survival.3,4
- BCMA is expressed in 100% of multiple myeloma patients, making it an ideal target5,6
Internet Explorer is no longer supported.
To provide you with the best possible experience, please switch to a supported browser e.g.
has been added to your basket